GlaxoSmithKline PLC ADR Cash Flow Conversion Efficiency
GlaxoSmithKline PLC ADR cash flow conversion efficiency. Based on the latest financial reports, GlaxoSmithKline PLC ADR (GSK) has a cash flow conversion efficiency ratio of 0.149x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.54 Billion) by net assets ($17.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GlaxoSmithKline PLC ADR (1990–2025)
Cash flow conversion efficiency of GlaxoSmithKline PLC ADR from 1990 to 2025. This chart illustrates how GlaxoSmithKline PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GlaxoSmithKline PLC ADR stock quote for real-time trading data and today's change.
GlaxoSmithKline PLC ADR Cash Flow Conversion Ratio Explained
GlaxoSmithKline PLC ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GlaxoSmithKline PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline PLC ADR ranked by their cash flow conversion efficiency. Also see how much is GlaxoSmithKline PLC ADR worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rio Tinto Group
MX:RION
|
0.042x |
|
UNICREDIT S.P.A. ADR
F:CRIP
|
N/A |
|
ServiceNow Inc
NYSE:NOW
|
0.173x |
|
BNP Paribas SA
PA:BNP
|
0.132x |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
0.073x |
|
Canadian Imperial Bank Of Commerce
TO:CM
|
0.246x |
|
Rio Tinto Group
F:RIOA
|
0.042x |
|
DBS GROUP ADR/4 SD 1
F:DEV
|
N/A |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline PLC ADR (1990–2025)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline PLC ADR from 1990 to 2025. Review GlaxoSmithKline PLC ADR free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.99 Billion | $7.14 Billion | 0.447x | -10.83% |
| 2024-12-31 | $13.09 Billion | $6.55 Billion | 0.501x | +3.53% |
| 2023-12-31 | $16.31 Billion | $7.89 Billion | 0.484x | -34.02% |
| 2022-12-31 | $10.10 Billion | $7.40 Billion | 0.733x | +166.55% |
| 2021-12-31 | $28.91 Billion | $7.95 Billion | 0.275x | -7.30% |
| 2020-12-31 | $28.44 Billion | $8.44 Billion | 0.297x | -10.01% |
| 2019-12-31 | $24.32 Billion | $8.02 Billion | 0.330x | -85.62% |
| 2018-12-31 | $3.67 Billion | $8.42 Billion | 2.293x | +15.66% |
| 2017-12-31 | $3.49 Billion | $6.92 Billion | 1.983x | +51.46% |
| 2016-12-31 | $4.96 Billion | $6.50 Billion | 1.309x | +352.40% |
| 2015-12-31 | $8.88 Billion | $2.57 Billion | 0.289x | -72.41% |
| 2014-12-31 | $4.94 Billion | $5.18 Billion | 1.049x | +13.43% |
| 2013-12-31 | $7.81 Billion | $7.22 Billion | 0.924x | +42.57% |
| 2012-12-31 | $6.75 Billion | $4.38 Billion | 0.648x | -8.42% |
| 2011-12-31 | $8.83 Billion | $6.25 Billion | 0.708x | +1.52% |
| 2010-12-31 | $9.74 Billion | $6.80 Billion | 0.697x | -4.45% |
| 2009-12-31 | $10.74 Billion | $7.84 Billion | 0.730x | -16.95% |
| 2008-12-31 | $8.32 Billion | $7.31 Billion | 0.879x | +41.24% |
| 2007-12-31 | $9.91 Billion | $6.17 Billion | 0.622x | +47.22% |
| 2006-12-31 | $9.65 Billion | $4.08 Billion | 0.423x | -48.37% |
| 2005-12-31 | $7.57 Billion | $6.20 Billion | 0.819x | -1.65% |
| 2004-12-31 | $5.94 Billion | $4.94 Billion | 0.832x | +45.05% |
| 2003-12-31 | $8.45 Billion | $4.85 Billion | 0.574x | +38.56% |
| 2002-12-31 | $7.39 Billion | $3.06 Billion | 0.414x | -24.54% |
| 2001-12-31 | $8.40 Billion | $4.61 Billion | 0.549x | +165.41% |
| 2000-12-31 | $8.96 Billion | $1.85 Billion | 0.207x | +29.48% |
| 1999-12-31 | $3.19 Billion | $510.00 Million | 0.160x | +7.83% |
| 1998-12-31 | $2.77 Billion | $410.00 Million | 0.148x | -54.48% |
| 1997-12-31 | $1.89 Billion | $615.00 Million | 0.325x | -51.44% |
| 1996-12-31 | $1.27 Billion | $849.00 Million | 0.670x | -88.17% |
| 1995-12-31 | $221.00 Million | $1.25 Billion | 5.665x | +32.94% |
| 1994-12-31 | $574.69 Million | $2.45 Billion | 4.261x | +1983.79% |
| 1993-12-31 | $5.15 Billion | $1.05 Billion | 0.205x | +2.74% |
| 1992-12-31 | $4.66 Billion | $927.00 Million | 0.199x | +10.25% |
| 1991-12-31 | $3.64 Billion | $657.00 Million | 0.181x | -3.65% |
| 1990-12-31 | $3.28 Billion | $615.00 Million | 0.187x | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more